Avalo Therapeutics, Inc. (AVTX)
About Avalo Therapeutics, Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $59.0K
- Net income
- -$78.3M
- Total assets
- $116.5M
- Market cap
- $975.5M
- Operating margin
- -123601.7%
- Net margin
- -132642.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $59.0K
- Operating expenses
- $73.0M
- Operating income
- -$72.9M
- Income tax
- $165.0K
- Net income
- -$78.3M
- EPS (basic)
- $-5.84
- EPS (diluted)
- $-5.84
Balance sheet
- Total assets
- $116.5M
- Current assets
- $105.3M
- Total liabilities
- $33.4M
- Current liabilities
- $12.9M
- Shareholders’ equity
- $83.0M
Cash flow
- Operating cash flow
- -$51.5M
- Investing cash flow
- -$81.7M
- Financing cash flow
- $14.6M
- Net cash flow
- -$118.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $975.5M
- EPS (diluted)
- $-5.84
- Shares outstanding
- 52.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 13, 2015
Avalo Therapeutics, Inc. (AVTX) Stock Price
- Reported a net loss of $78.3M in FY2025.
- Revenue declined 99% from FY2021 to FY2025.
- Trading 19% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Avalo Therapeutics, Inc..
Write a review
News about Avalo Therapeutics, Inc.
News & sentiment via Polygon.io
Avalo Therapeutics, Inc.: frequently asked questions
Is Avalo Therapeutics, Inc. an American company?
Avalo Therapeutics, Inc. is a US-based company headquartered in Wayne, Pennsylvania, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Avalo Therapeutics, Inc. headquartered?
Avalo Therapeutics, Inc. is headquartered in Wayne, Pennsylvania, United States.
Is Avalo Therapeutics, Inc. publicly traded?
Yes — Avalo Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol AVTX on the NASDAQ.
What does Avalo Therapeutics, Inc. do?
Avalo Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
